Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 9Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 39Genitourinary 23Thoracic 11Breast 10Other hematologic neoplasm 8Lymphoid 4Sarcoma 3Head & Neck 3Endocrine 3Tumor-Agnostic 2Plasma cell 2Myeloid 2Gynecologic 2CNS 2Other solid neoplasm 1Dermatologic 1Classical hematology 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Sorafenib × Gynecologic × Clear all
NCT00526799 2016-03-03

Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

Hoosier Cancer Research Network

Phase 1/2 Terminated
30 enrolled 16 charts
Gynecologic

Ovarian Neoplasms

NCT00522301 2016-02-29

Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
6 enrolled 5 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡